Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) November 16, 2017 NEW YORK , Nov. 16, 2017 (GLOBE NEWSWIRE) Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that data from the Phase 2 trial of SL-701 in patients with second-line glioblastoma (GBM)

November 16, 2017

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting November 1, 2017 NEW YORK , Nov. 01, 2017 (GLOBE NEWSWIRE) Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in four presentations at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12,…

November 1, 2017

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint October 31, 2017 NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that the pivotal Phase 2 trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has met its primary endpoint. Based on…

October 31, 2017

Stemline Therapeutics to Present at Upcoming Investor Conferences September 20, 2017 NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D., Stemline’s CEO, will be presenting at two upcoming investor conferences.

September 20, 2017